DaVita Inc. (DVA) stock analysis
Close on Nov 11, 2026Market cap $11.54BP/E 13.5Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Mixed13 of 30 checks passed
DaVita passes 13 of the 30 checks behind our score; 11 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 5/6
- Growth
- 4/6
- Past performance
- 3/6
- Financial health
- 1/6
- Dividend
- 0/6
What stands out
Margin of safety over 20%
The price is 41.2% below fair value, more than the 20% cushion we look for.
Trading below fair value
The share price of $183.50 is below our fair value estimate of $312.00.
Return on capital over 10%
Return on invested capital was 18.1%, above the 10% that usually covers the cost of capital.
EPS growing 10%+ a year
Diluted EPS grew 18.9% a year over the last three fiscal years.
What to watch
Earnings shrank over 5 years
Net income shrank 0.7% a year on average over the last five fiscal years.
Revenue growing under 10% a year
Revenue grew 5.5% a year over the last three fiscal years, short of the 10% we look for.
Debt not well covered by cash flow
Operating cash flow over the last twelve months equals 17.4% of total debt; we look for at least 20%.
Elevated bankruptcy risk
The Altman Z-score is 1.71; above 3 is the safe zone and below 1.8 the distress zone.
Valuation5/6
P/E below its 5-year median
DaVita's P/E of 13.5 is below its own 5-year median of 14.7.
P/E below the industry
DaVita's P/E of 13.5 is below the Health Services median of 23.9.
EV/EBITDA above its 5-year median
DaVita's EV/EBITDA of 7.8 is above its 5-year median of 7.8.
P/S below the industry
DaVita's price-to-sales of 0.81 is below the Health Services median of 1.33 (book value is negative, so we use sales).
Trading below fair value
The share price of $183.50 is below our fair value estimate of $312.00.
Margin of safety over 20%
The price is 41.2% below fair value, more than the 20% cushion we look for.
Growth4/6
Revenue growing under 10% a year
Revenue grew 5.5% a year over the last three fiscal years, short of the 10% we look for.
EPS growing 10%+ a year
Diluted EPS grew 18.9% a year over the last three fiscal years.
Earnings growth accelerating
Net income grew 19.2% over the last twelve months, against a 5-year average of -0.7% a year.
Growing faster than the industry
Revenue grew 6.4% over the last twelve months; the Health Services median is 2.0%.
Guidance raised
DaVita raised its Current 2026 guidance Adjusted operating income outlook on May 5, 2026.
Gross margin trend
This company does not report gross profit.
Past performance3/6
Return on equity
Needs positive equity and five years of results.
Return on capital over 10%
Return on invested capital was 18.1%, above the 10% that usually covers the cost of capital.
Return on equity against the industry
Needs positive equity.
Earnings shrank over 5 years
Net income shrank 0.7% a year on average over the last five fiscal years.
Net margin above its 5-year average
Net margin was 6.5% over the last twelve months, against a 5-year average of 6.3%.
Net margin above the industry
DaVita's net margin of 6.5% is above the Health Services median of -1.0%.
Financial health1/6
Debt level
Needs debt and equity figures.
Debt trend
Needs a balance sheet from five years ago with positive equity.
Debt not well covered by cash flow
Operating cash flow over the last twelve months equals 17.4% of total debt; we look for at least 20%.
Interest coverage
Interest expense is not reported separately.
Short-term assets cover short-term debts
Current assets are 1.41 times current liabilities.
Elevated bankruptcy risk
The Altman Z-score is 1.71; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
DaVita has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itOur estimate per share
$312.00
The share price is 41% below this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| P/E | 19.3× | 14.7× | 23.9× | $261.61 | 44% |
| EV/EBITDA | 11.9× | 7.8× | 16.2× | $371.94 | 39% |
| Earnings power | 7.4% cost of equity | – | – | $306.50 | 17% |
| Fair value | $312.00 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/E at month end
- Own 5-year median 14.7
- Health Services median 23.9
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Low risk
- Average value traded per day
- $140.52M
- Value traded per 1% price move
- $79.33M
Downside
High risk
- Typical loss in a bad month
- 25.1%
- Volatility (annualized)
- 47%
- Sharpe ratio, 1 year
- 1.03
- Beta to the S&P 500 (5Y)
- 0.37
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +6.5% | +5.5% | +3.4% | – | |
| Operating income | -2.2% | +15.1% | +3.8% | +6.0% | |
| Net income | -20.2% | +10.0% | -0.7% | +10.7% | |
| EPS, diluted | -8.3% | +18.9% | +9.3% | +22.9% | |
| Free cash flow | -10.6% | +10.9% | +0.1% | +4.4% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 18.5% | 44.0% | -281.8% | |
| Return on assets | 4.7% | 4.5% | 4.3% | |
| Current ratio | 1.47 | 1.27 | 1.29 | |
| Debt to equity | 1.96 | 5.84 | -15.78 | |
| Net debt to EBITDA | 3.34× | 3.28× | 3.49× | |
| Interest coverage | 5.2× | 6.0× | 3.8× | |
| Capex to revenue | 7.7% | 5.8% | 4.2% | |
| Diluted shares | 205M | 123M | 76M |
Where the cash went
Fiscal 2021 to 2025, five years combined
DaVita generated $9.46B from operations and spent $8.25B on capital expenditure, dividends and share buybacks. 36% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 5.5% | 0.78× | -65.60× | -281.8% |
| FY2024 | 7.3% | 0.75× | 29.03× | 159.1% |
| FY2023 | 5.7% | 0.72× | 19.13× | 78.2% |
| FY2022 | 4.8% | 0.68× | 23.20× | 76.4% |
| FY2021 | 8.4% | 0.68× | 15.95× | 91.5% |
| FY2020 | 6.7% | 0.67× | 9.75× | 44.0% |
| FY2019 | 7.1% | 0.63× | 6.24× | 27.8% |
| FY2018 | 1.4% | 0.60× | 4.54× | 3.8% |
| FY2017 | 6.1% | 0.58× | 4.04× | 14.2% |
| FY2016 | 8.2% | 0.57× | 3.92× | 18.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$746.80M
- Cash generatingOperating cash flow above zero$1.89B
- Return on assets improvedROA up on the prior year5.5% → 4.3%
- Earnings backed by cashOperating cash flow above net income$1.89B vs $746.80M
- Less leverageLong-term debt to assets fell53.1% → 58.1%
- Better liquidityCurrent ratio rose1.26 → 1.29
- No dilutionShare count did not rise87M → 76M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.76 → 0.79
See a number that looks wrong?